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Objectives:Transcranial direct current stimulation (tDCS) has demonstrated some efficacy
in treatment-resistant major depression (TRD). The majority of previous controlled studies
have used anodal stimulation to the left dorsolateral prefrontal cortex (DLPFC) and a control
location such as the supraorbital region for the cathode. Several open-label studies have
suggested effectiveness from anodal stimulation to the left DLPFC combined with catho-
dal stimulation to the right DLPFC. Thus, this study evaluated the efficacy of tDCS using
anodal stimulation to the left DLPFC and cathodal stimulation to the right DLPFC compared
to sham tDCS. Methods: Subjects between the ages of 18 and 65 were recruited from
a tertiary care university hospital. Twenty-four subjects with TRD and a 17-item Hamilton
Rating Scale for Depression greater than 21 were randomized to receive tDCS or sham
tDCS.The rates of remission were compared between the two treatment groups. Results:
The remission rates did not differ significantly between the two groups using an intention
to treat analysis. More subjects in the active tDCS group had failed a course of electrocon-
vulsive therapy in the current depressive episode. Side effects did not differ between the
two groups and in general the treatment was very well tolerated. Conclusion: Anodal stim-
ulation to the left DLPFC and cathodal stimulation to the right DLPFC was not efficacious in
TRD. However, a number of methodological limitations warrant caution in generalizing from
this study. Ongoing, controlled studies should provide further clarification on the efficacy
of this stimulation configuration in TRD. ClinicalTrials.gov Identifier: NCT01078948.
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INTRODUCTION
Major Depressive Disorder (MDD) is a highly prevalent mental
illness (Kessler et al., 2003; Patten et al., 2006). Despite the vast
number of pharmacological and psychotherapeutic treatments
that are available, as many as 50% of patients fail to respond to
treatment (Pincus and Pettit, 2001; Sackeim, 2001; Fava, 2003).
In addition, the pharmacological augmentation and combination
strategies frequently used in treatment-resistant depression (TRD)
often increase the risk of adverse events and drug interactions (Joo
et al., 2002; Dew et al., 2007; Papakostas, 2008). Electroconvulsive
therapy (ECT) has demonstrated superior efficacy outcomes in
TRD (Eranti et al., 2007; Lisanby, 2007). However, many patients
are reluctant to engage in a trial due to stigma and the risk of
cognitive adverse effects (Lisanby, 2007). The need for alternative
treatment strategies to optimize outcomes for patients who expe-
rience TRD has been recognized as one of the future directions for
addressing this disorder (Insel, 2006).
Transcranial direct current stimulation (tDCS) is a non-
invasive and non-convulsive form of brain stimulation in which a
weak, direct current (typically 1–2 mA) is applied using two sur-
face scalp electrodes. Initial studies in animals suggested that such
stimulation could elicit polarity-dependent alterations in cortical
excitability and activity, with anodal stimulation increasing corti-
cal excitability and cathodal stimulation causing cortical inhibition
(Bindman et al., 1964). Furthermore, these resultant changes were
not limited solely to the period of stimulation, but endured for
minutes to hours afterward (Bindman et al., 1964). More recently,
Nitsche and Paulus (2001) demonstrated that comparable changes
occurred following tDCS directed to the human motor cortex,
providing further evidence of its neuromodulatory potential.
As a result of its capacity to alter cortical activity, investigators
in the 1960s began to investigate tDCS as a possible treatment
for depression (Costain et al., 1964; Lippold and Redfearn, 1964;
Redfearn et al., 1964); however, results were mixed, methodolog-
ical differences between studies confounded results, interest in
pursuing tDCS waned and the development of pharmacologi-
cal antidepressant agents dominated the ensuing decades. Since
the 1990s, however, research in various forms of invasive and
non-invasive brain stimulation such as deep brain stimulation
(DBS) and repetitive transcranial magnetic stimulation (rTMS)
has been re-invigorated. A resurgence of interest may be partially
a consequence of the recognition that, despite advances in phar-
macotherapy, treatment-resistance remained a persistent issue in
the treatment of depression (Fava, 2003; Rush et al., 2006).
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In spite of renewed interest in examining tDCS as a potential
treatment for major depression, its efficacy, as well as its optimal
stimulation parameters, have yet to be established. A recent meta-
analysis that reviewed 10 studies (six of which were randomized
controlled trials) reported that compared to sham tDCS, active
tDCS was more effective in reducing symptoms of depression
(Kalu et al., 2012). The authors caution, though, that the small
number of studies hindered their meta-analysis, many of which
had limited sample sizes, eligible for inclusion. A large, randomized
sham-controlled trial that used anodal stimulation over the left
dorsolateral prefrontal cortex (DLPFC) and cathodal stimulation
over the contralateral supraorbital region showed a significantly
greater improvement in depression scores in subjects receiving
active tDCS compared to sham over a 3-week controlled phase,
although differences in response or remission criteria were not
demonstrated. However, after an additional 3 weeks in an open-
label extension phase, those subjects who had received active stim-
ulation were significantly more likely to achieve a 50% reduction
in symptoms (Loo et al., 2012).
Although the pathophysiology and etiology of major depres-
sion is complex, one hypothesis underlying a number of brain
stimulation studies is that there exists a pathological aberration
and imbalance in the activity of the left and right prefrontal
cortices, with the left DLPFC hypoactive and right DLPFC over-
active in those with depression (Baxter et al., 1989; Fitzgerald
et al., 2008; Grimm et al., 2008). With the aim of ameliorat-
ing this putative imbalance between the two hemispheres, many
brain stimulation studies attempt to enhance the excitability of
the left DLPFC while dampening the activity of the right pre-
frontal cortex (Fitzgerald et al., 2006; Blumberger et al., 2011).
Though there is much debate in the ECT literature regard-
ing the efficacy of unilateral and bilateral treatment, it is clear
that both forms of stimulation involve widely distributed neu-
robiological change as a consequence of seizure generalization
(Nobler et al., 2001). A recent brain imaging study has demon-
strated that tDCS can produce electrode dependent changes in
regional brain activity in the prefrontal cortex (Merzagora et al.,
2010). Thus, there is a rationale for directing anodal tDCS over
the left DLPFC, while placing cathodal stimulation over the
right DLPFC.
The optimal placement of the electrodes remains under inves-
tigation – several tDCS studies, using bilateral frontal stimulation
that resulted in an improvement of depressive symptoms, have
positioned the cathode over the right supraorbital region rather
than over the right DLPFC (Fregni et al., 2006a; Boggio et al.,
2008; Loo et al., 2010). Moreover, as regions other than the pre-
frontal cortices have also been implicated in depression, it may be
prudent to explore the effects of alternative electrode montages
on the efficacy of tDCS. Another recent open-label, pilot study
used fronto-extracephalic stimulation, in which anodal stimula-
tion was directed over the right DLPFC and cathodal stimulation
was directed over the right, upper arm (Martin et al., 2011). The
subjects had previously participated in a tDCS trial that delivered
bifrontal stimulation and subjects experienced the two treatment
groups consecutively. The authors reported a 43.8% reduction in
depression scores with a more rapid response when compared to
bilateral frontal stimulation.
The relationship between degree of symptom severity and
treatment-resistance is intrinsic to the question of efficacy of
tDCS treatment. Many earlier studies that demonstrated promis-
ing results, included individuals experiencing mild to moderate
depression and did not necessitate that participants meet criteria
for treatment-resistance (Fregni et al., 2006a; Boggio et al., 2008;
Rigonatti et al., 2008). Several, open-label studies have suggested
that left DLPFC cathodal and right DLPFC anodal tDCS may be
an effective treatment configuration in more severely depressed
patients (Ferrucci et al., 2009; Brunoni et al., 2011a; Dell’Osso
et al., 2011). Thus, the current study was designed to determine
the efficacy of tDCS providing both left and right DLPFC stim-
ulation using anodal and cathodal stimulation respectively. We
hypothesized that this electrode placement configuration would
lead to greater improvement compared to sham, with a larger
effect size than previous unilateral approaches with anodal stim-
ulation of the left DLPFC and cathodal stimulation over the
supraorbital region. In addition, we hypothesized that tDCS would
be as tolerated as well as sham stimulation with minimal side
effects.
METHODS
SUBJECTS
Twenty-four outpatients (20 female, 4 male; mean age 47.3 years,
range 24–62) were recruited from the Mood and Anxiety, Geriatric
Mental Health, and Brain Stimulation Treatment and Research
programs at the Centre for Addiction and Mental Health (a ter-
tiary university teaching hospital) as well as via referrals from
physicians in Ontario, Canada. All subjects had a diagnosis of
unipolar Major Depressive Disorder without psychotic features
and were experiencing a Major Depressive Episode, as confirmed
by the Structured Clinical Interview for the DSM-IV (SCID-IV).
Subjects were required to have a score of ≥21 on the 17-item
Hamilton Rating Scale for Depression (HRSD-17). Subjects were
required to meet stage II criteria on the Thase Scale for treatment-
resistance (failure to achieve remission or inability to tolerate
two trials of an antidepressant from separate classes; Thase and
Rush, 1995). Concomitant medications, such as various classes of
antidepressants (e.g., selective serotonin reuptake inhibitors, tri-
cyclic antidepressants), benzodiazepines, and antipsychotics were
permitted provided that subjects had been on a stable dose of
their medications for at least 4 weeks prior to entering the study
and were able to maintain those stable dosages for the duration
of the protocol. Subjects taking anticonvulsants were ineligible
for the study, as certain agents have been found to disrupt the
effects of anodal tDCS (Nitsche et al., 2003). Moreover, indi-
viduals were not included in the study if they: (i) had a DSM-
IV history of substance abuse or dependence in the 6-months
prior to enrolling in the study; (ii) had a concomitant, major
and unstable medical, or neurologic illness; (iii) had a history
of seizures; (iv) were pregnant; and/or (v) met DSM-IV criteria
for borderline personality disorder or antisocial personality disor-
der based on the SCID for DSM-IV Axis II Disorders (SCID-II).
The research ethics board at the Centre for Addiction and Men-
tal Health approved the study and all subjects provided written,
informed consent prior to commencing their involvement in the
trial.
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STUDY DESIGN AND TREATMENT
Following completion of baseline clinical measures, subjects were
randomly assigned using a computer-generated randomization list
with the information stored on a centralized computer to receive
either active or sham tDCS. Only the treating clinician was aware
of subjects’ treatment condition. Fifteen treatments, each lasting
20 min, were administered over the course of 3 weeks (one treat-
ment per weekday) with clinical raters and subjects blind to treat-
ment group allocation. After receiving seven treatment sessions,
subjects were assessed using the Montgomery–Asberg Depression
Rating Scale (MADRS; Montgomery and Asberg, 1979) and con-
tinued with the remainder of their treatment course, whereupon
they were reassessed with the full clinical rating battery and the
blind was broken. During the informed consent process, subjects
were told that there were two treatment conditions (i.e., active
or sham stimulation) and were instructed not to discuss their
treatment experiences with the clinical rater.
At the time of the study design, there was no data on the bilat-
eral electrode placement proposed. However, we postulated that
46 patients would be required to have a 80% chance of detecting,
as significant at the 5% level, a decrease in the primary outcome
measure from 8 in the sham group to 15 in the active tDCS group.
We planned an interim analysis at the midpoint of the trial.
TREATMENT PROTOCOL
Transcranial direct current stimulation treatment was delivered
using a battery-operated, constant current stimulator (CX-6650;
Rolf Schneider Electronics, Germany) and transmitted by two rub-
ber electrodes (7 cm× 5 cm= 35 cm2), each covered by a saline-
soaked sponge and affixed to the head with a headband. The anode
was directed over the left DLFPC and the cathode was placed
over the right DLPFC, corresponding to electrodes F3 and F4,
respectively, according to the 10–20 EEG system. Neuronavigation
studies (Herwig et al., 2001) have indicated that this is a reasonably
accurate method of locating the DLPFC, and it has also been used
in previous tDCS studies targeting the DLPFC (Fregni et al., 2005,
2006a). In the active treatment group, stimulation was delivered at
2 mA for 20 min; sham stimulation was delivered using parameters
identical to those in the active condition with the exception of the
stimulator being programmed to turn off after 30 s, allowing the
investigators to mimic the initial somatic sensations experienced
with active tDCS, but without providing putative therapeutic ben-
efits (Gandiga et al., 2006; Ambrus et al., 2010). In both treatment
arms, the stimulator was oriented in such a way that subjects were
unable to view the settings of the treatment parameters on the
front panel of the machine. Subjects were permitted to make up
missed treatments; however, they were not allowed to miss more
than four treatments over the duration of the study.
CLINICAL ASSESSMENTS
Experienced clinical raters blind to treatment assignment adminis-
tered the following rating scales at baseline and post-treatment: the
MADRS, HRSD-17 (Hamilton, 1967), the Brief Psychiatric Rat-
ing Scale (Overall and Gorharn, 1962), and the Beck Depression
Inventory (BDI; Beck et al., 1961). Subjects underwent an abbrevi-
ated assessment at the trial midpoint (i.e., after seven treatments)
consisting of the MADRS only.
OUTCOME MEASURES
The primary outcome for the study was change from baseline to
endpoint on the HRSD-17. All subjects were assessed at base-
line, at the point of early treatment termination, if possible,
and after 15 treatments. Secondary outcomes included remission
(score ≤7) and response (50% improvement). Other measures
included change from baseline to endpoint, as well as response
and remission on MADRS and BDI-II.
DATA ANALYSIS
All statistical analyses were conducted using statistical software
(SPSS for Windows 15.0; SPSS Inc., Chicago, IL, USA) and the
analysis was conducted on an intention to treat basis. Baseline
differences in demographic and clinical variables were compared
between treatment groups. Continuous variables were analyzed
with one-way analysis of variance (ANOVA). Categorical variables
were analyzed with a two-tailed Fisher’s exact test (for dichoto-
mous comparisons). All procedures were two-tailed and we used a
significance level set at α= 0.05 for the primary outcome. Analysis
of the primary outcome was performed using repeated measures
ANOVA.
RESULTS
PARTICIPANT FLOW, FOLLOW-UP, AND SAMPLE CHARACTERISTICS
Of 47 patients screened, 4 did not meet eligibility criteria and 19
declined participation. A total of 24 patients were randomized (see
Figure 1).
The subjects’ baseline clinical and demographic characteristics
are summarized in Table 1. There were no clinically important
differences between groups. Nineteen subjects were taking anti-
depressant medication (with or without other agents) during the
trial. There were no differences in the proportion of subjects tak-
ing any of the medication classes. Six subjects in the tDCS group
and two subjects in the sham group had received treatment with
ECT in previous depressive episodes. Three subjects in the tDCS
group and one in the sham group had failed a course of ECT dur-
ing the current depressive episode. Post-treatment (week 1) data
on the primary outcome measure was available for n= 21 sub-
jects (87.5%). Subjects who were lost to follow-up did not differ
from retained subjects on any of the baseline clinical, cognitive,
or demographic variables. Nineteen subjects received all 15 treat-
ments, of the remaining five subjects the number of missed treat-
ments were 14, 12, 4, 1, 7 respectively. Of a total of 19 subjects who
were assessed for maintenance of the blind, 14 subjects (73.7%)
correctly guessed whether they received active or sham treatment: 6
(60.0%) in the active tDCS group and 8 (88.9%) in the sham group.
These proportions did not differ significantly between the two
groups (p= 0.30). The blinding of clinical raters was not assessed.
PRIMARY OUTCOME: CHANGE IN HRSD-17
The mean post-HRSD score in the active tDCS group and sham
stimulation group are shown in Table 2. There was no differ-
ence in HRSD change between the two groups (F = 0.063; df= 1;
p= 0.80). The same analysis was run for all subjects who com-
pleted all 15 treatments. Similarly, there was no difference in HRSD
change between the two groups (F = 0.30; df= 1; p= 0.59). None
of the subjects in either group met criteria for remission on the
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Assessed for eligibility (n = 47) 
Excluded (n = 23) 
♦ Not meeting inclusion criteria (n = 4) 
♦ Declined to participate (n = 19) 
Analyzed (n = 13) 
♦ Excluded from analysis (give reasons) (n=0)
Lost to follow-up (n = 2): did not or were unable to 
complete post-treatment measures 
Discontinued intervention (n = 1): did not want to 
continue in study due to scalp discomfort 
Allocated to active tDCS (n = 13) 
♦ Received allocated intervention (n = 13)
♦ Did not receive allocated intervention (n = 0)
Lost to follow-up (n = 0) 
Discontinued intervention (n = 3): exceeded 
number of treatments allowed to miss in study 
Allocated to sham tDCS (n = 11) 
♦ Received allocated intervention (n = 10)
♦ Did not receive allocated intervention (n = 1) 
             Could no longer make time commitment for  
        study
Analyzed (n = 11) 
♦ Excluded from analysis (give reasons) (n=0)
Allocation 
Analysis 
Follow‐Up 
Randomized (n = 24) 
Enrollment 
FIGURE 1 | CONSORT flow chart of the study. The study was registered at URL: http://clinicaltrials.gov/show/NCT01078948 (ID:NCT01078948).
HRSD. One subject in each group met criteria for response on the
HRSD (Fisher’s exact p= 1.00).
SECONDARY OUTCOME MEASURES
Montgomery-Asberg depression rating scale
The mean post-MADRS score in the active tDCS group and
sham stimulation group are shown in Table 2. There was no
difference in MADRS change between the two groups (F = 0.38;
df= 1; p= 0.55). One of the subjects in the active tDCS group
achieved response (Fisher’s exact p= 1.00) and remission crite-
ria (Fisher’s exact p= 1.00) while no subjects met response or
remission criteria in the sham stimulation group.
Beck depression inventory-II
The mean post-BDI-II score in the active tDCS group and sham
stimulation group are shown in Table 2. There was no differ-
ence in BDI-II change between the two groups (F = 1.1; df= 1;
p= 0.38). Two of the subjects in the active tDCS group and one in
the sham stimulation group achieved remission criteria (Fisher’s
exact p= 1.00). Three subjects in the active tDCS group and one
in the sham stimulation group met criteria for response (Fisher’s
exact p= 0.58).
ADVERSE EFFECTS AND TOLERABILITY
As indicated, 3/24 subjects (28%) did not complete an endpoint
assessment for the primary outcome: 2/13 in the active tDCS group
and 1/11 in the sham group (see Figure 1). Three subjects had
an endpoint assessment but did not receive all 15 treatments as
they missed too many sessions and were withdrawn. Four sub-
jects in the sham group reported mild skin tingling. Two subjects
in the active group reported mild skin tingling and two reported
mild to moderate skin tingling. Three subjects in the active group
reported mild headache while no subjects reported headache in
the sham group. No serious adverse events were reported during
the trial. One subject in the sham group withdrew due to scalp
discomfort.
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Table 1 | Demographic and baseline clinical characteristics.
Characteristic tDCS (n=13) Sham (n=11)
DEMOGRAPHICS
Age, years (mean, SD) 45.3 (11.6) 49.7 (9.4)
Gender, M/F 3/10 1/10
One or more medical illnesses 9 (69.2) 6 (54.5)
DEPRESSION HISTORY
Recurrent episodes (%) 13 (100) 9 (81.8)
Current episode severe (%) 1 (7.7) 0 (0)
Current episode moderate (%) 12 (92.3) 11 (100)
Atypical features (%) 1 (7.7) 1 (9.1)
Melancholic features (%) 1 (7.7) 1 (9.1)
Comorbid anxiety (%) 4 (30.8) 1 (9.8)
Number of depressive episodes
(mean, SD)
2.9 (2.3) 3.8 (3.7)
Duration of current episode in years
(mean, SD)
4.3 (5.6) 3.4 (3.0)
Baseline HRSD (mean, SD) 24.9 (3.1) 24.1 (2.9)
Baseline MADRS (mean, SD) 31.5 (5.8) 32.0 (7.0)
Baseline BDI-II (mean, SD) 35.4 (8.1) 36.4 (6.8)
Baseline BPRS (mean, SD) 32.0 (3.3) 31.4 (3.7)
TREATMENT HISTORY
SSRI (%) 2 (15.4) 2 (18.2)
SNRI (%) 7 (53.8) 2 (18.2)
Tricyclic antidepressant (%) 2 (15.4) 1 (9.1)
Mirtazapine (%) 1 (7.7) 2 (18.2)
Bupropion (%) 4 (30.8) 3 (27.3)
Antipsychotic augmentation (%) 1 (7.7) 1 (9.1)
Med combination (%) 9 (69.2) 8 (72.7)
Benzodiazepine Use (%) 6 (46.2) 2 (18.2)
History of ECT (%) 6 (46.2) 2 (18.2)
ECT failure in the current episode (%) 3 (23) 1 (9.1)
No antidepressant (%) 2 (15.4) 3 (27.3)
Number of failed antidepressant trials
(mean, SD)
4.3 (2.4) 4.1 (2.2)
DISCUSSION
To our knowledge this is the first randomized sham-controlled
trial comparing tDCS that employed anodal stimulation to the
left DLPFC and cathodal stimulation to the right DLPFC. We did
not find any differences between the efficacy of active and sham
stimulation. Both treatment groups improved over the 3-weeks of
the trial. Overall, the treatment was well tolerated with only one
subject withdrawing due to scalp discomfort.
The strengths of this study included focus on inclusion of
treatment-resistant subjects with stage II or higher treatment-
resistance (Thase and Rush, 1995), the use of sham tDCS as a
control, and an increase in the number of treatments to 15 over
3 weeks (longer than most previous treatment trials).
A number of potential limitations may explain the lack of
efficacy from active tDCS in the current study. The most impor-
tant limitation is the small sample size of the study. Despite the
clear lack of separation between the two conditions, it is possi-
ble that differences may have been demonstrated had the study
continued to its anticipated sample size of 46. Given the lack of
Table 2 | Primary and secondary outcome measures (mean, SD) at
baseline and post-treatment.
Baseline Post-treatment
PRIMARY OUTCOME
HRSD-17 scores tDCS
(n=13)
sham
(n=11)
tDCS
(n=13)
sham
(n=11)
24.9 (3.1) 24.1 (2.9) 18.8 (4.77) 18.1 (5.5)
SECONDARY OUTCOMES
MADRS scores 31.5 (5.8) 32.0 (7.0) 25.4 (5.2) 27.7 (6.4)
BDI-II scores 35.4 (8.1) 36.4 (6.8) 23.0 (13.8) 26.4 (8.6)
differences between groups and the interim analysis we felt that
continuing the study would not be ethical. Though we sought to
include patients with treatment-resistance, the level of treatment-
resistance may have been too high to observe an effect. Indeed,
a third of the sample in the active stimulation group had failed
a course of ECT in the current episode and nearly half had ECT
in previous episodes. Though the number of subjects who failed
a course of ECT in the active tDCS group was not statistically
different from the number that failed a course of ECT in the
sham group, the active group may have been biased toward non-
response due to the small numbers in the study. Failure of ECT
has generally been an exclusion criterion in other brain stimu-
lation trials (Fregni et al., 2006b; O’Reardon et al., 2007; George
et al., 2010). Future controlled trials should ensure that subjects
with excessively high levels of treatment-resistance are character-
ized and accounted for in the randomization by stratification or
excluded from the eligibility criteria. Another major limitation of
the study is the high overall correct guess of treatment condition
in the study. The correct guess rate calls into question the ade-
quacy of the blinding and thus the sham control in this study.
However, the sham procedure in the current study followed the
directions and recommendations of previous studies (Gandiga
et al., 2006; Ambrus et al., 2010). Equal numbers of subjects in
both the sham and active group reported skin tingling suggest-
ing that the sham was effective at providing a somatic sensation.
However, more subjects in the active group reported headache and
more intense skin tingling. It is possible that the treating technician
gave non-verbal cues to subjects indicating treatment condition,
however, we have no way of assessing whether this occurred.
Though medication initiation was controlled in this study, the
possibility remains that subjects who started an antidepressant
immediately before study entry may have experienced a delayed
response (i.e., greater than 4 weeks) to their antidepressant dur-
ing the trial (Rush et al., 2003). However, the majority of subjects,
who were taking an antidepressant, had been on stable doses of
medication for longer than 8 weeks. Furthermore, the variability
in the use of any antidepressant may have impacted the effect of
the treatment. The use of benzodiazepines by patients may have
also limited the efficacy of the treatment as this class of medica-
tion has been shown to impair the neurophysiological effects of
stimulation (Nitsche et al., 2004). A greater percentage of patients
in the active stimulation group were taking benzodiazepines. In
addition, the patients in the active group had a longer duration
of illness and had failed more medication trials. Collectively, these
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differences suggest that the active stimulation group were more
treatment-resistant.
Notwithstanding these limitations, it is concerning that we
did not demonstrate differences on any of the primary or sec-
ondary outcome measures. None of the subjects in the study
met criteria for remission on the HRSD-17-item. A recent meta-
analysis has also concluded that the effects of tDCS are somewhat
muted (Kalu et al., 2012). A more recent randomized, double-
blind, sham-controlled study in patients who had failed to respond
to at least two previous trials of antidepressants from different
classes did not find a difference between active left DLFPC and
right supraorbital stimulation and sham stimulation of 2 weeks
duration (Palm et al., 2012). Subjective ratings on secondary out-
come measures, such as the Positive and Negative Affect Scale,
suggested that active tDCS was associated with an increase in
positive emotions and also trended toward a decrease of neg-
ative emotions (Palm et al., 2012). The largest study of tDCS
in depression has recently been reported and though there was
a significant difference in the change of MADRS scores, there
was no difference in responders and remitters between active
and sham stimulation (Loo et al., 2012). The authors suggested
that longer treatment durations up to 6 weeks might be neces-
sary to achieve clinical response with tDCS (Loo et al., 2012).
We hypothesized that providing excitatory stimulation (anode) to
the left DLPFC and inhibitory stimulation (cathode) to the right
DLPFC would lead to improved efficacy. The theoretical ratio-
nale for this comes from the ECT literature and some previous
rTMS studies showing improved efficacy with excitatory stimu-
lation to the left DLPFC and inhibitory stimulation to the right
DLPFC (Fitzgerald et al., 2006; Blumberger et al., 2011). However,
recent data has not replicated the finding of improved efficacy
with this stimulation pattern (Fitzgerald et al., 2012). Further-
more, it is possible that the montage of left and right DLPFC
were too close together leading to shunting over the scalp. While
it may be theoretically advantageous to stimulate bilaterally, the
physical properties of tDCS may not be amenable to this electrode
placement.
A series of three open-label trials have suggested that the stim-
ulation technique used in this study is an effective form of tDCS in
the treatment of depression (Ferrucci et al., 2009; Brunoni et al.,
2011a; Dell’Osso et al., 2011). One study showed a 30% improve-
ment in depression rating scale scores in 14 inpatients with a severe
major depressive episode using twice daily treatments. Similarly,
the other two studies found positive effects in both unipolar and
bipolar depressed patients after 10 treatments over 5 days (Brunoni
et al., 2011a; Dell’Osso et al., 2011). In contrast, we did not find
this stimulation configuration to be more beneficial than sham
stimulation when providing treatment once daily. However, we
would caution generalizing from the current study due to the
limitations identified. The design of the Sertraline vs. ELectrical
Current Therapy (SELECT) tDCS trial will utilize the same stimu-
lation parameters as the current study and should provide greater
clarification regarding the efficacy of anodal stimulation to the left
DLPFC and cathodal stimulation to the right DLPFC (Brunoni
et al., 2011b).
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